<DOC>
	<DOCNO>NCT02712983</DOCNO>
	<brief_summary>The purpose study support selection safe tolerable tobramycin inhalation powder ( TIP ) dose , regimen exhibit effective bacterial reduction P. aeruginosa non-cystic fibrosis bronchiectasis ( BE ) patient P. aeruginosa colonization .</brief_summary>
	<brief_title>Dose-finding Study Assess Efficacy , Safety Tolerability Tobramycin Inhalation Powder Patients With Non-Cystic Fibrosis Bronchiectasis Pulmonary P. Aeruginosa Infection</brief_title>
	<detailed_description>This blind , randomize , dose- regimen find trial active TIP dose placebo give addition local standard care .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . Male female patient ≥ 18 year age screening ( Visit 1 ) . Proven diagnosis nonCF BE document compute tomography highresolution compute tomography At least 2 exacerbation treat oral antibiotic OR 1 exacerbation require intravenous antibiotic treatment within 12 month prior screen . FEV1 ≥ 30 % predict screening ( Visit 1 ) . P. aeruginosa , must document respiratory sample least 1 time within 12 month also present expectorate sputum culture Visit 1 . Patients history cystic fibrosis . Patients primary diagnosis bronchial asthma . Patients primary diagnosis COPD associate least 20 pack year smoke history . Any significant medical condition either recently diagnose stable last 3 month , pulmonary exacerbation , opinion investigator make participation trial patient ' best interest . History hearing loss chronic tinnitus deem clinically significant investigator . Patients active pulmonary tuberculosis . Patients currently receive treatment nontuberculous mycobacterial ( NTM ) pulmonary disease . Patients regularly receive inhale antipseudomonal antibiotic ( study inhale antipseudomonal antibiotic allow study drug ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Inhaled tobramycin ; tobramycin inhalation powder ; bronchiectasis ; pulmonary Pseudomonas aeruginosa infection ; dose-finding study</keyword>
</DOC>